Three Separate Pancreatic Cancer Breakthroughs Hit at Once: A New Drug, an Off-the-Shelf Vaccine, and Real Patients Surviving

The Treatment Pipeline Just Got Crowded — In a Good Way

Mayo Clinic's AI can catch pancreatic cancer up to three years early. That was the detection story. This is the treatment story, and three separate advances are hitting the public record at roughly the same time: a targeted drug, an off-the-shelf vaccine, and a personalized mRNA vaccine. All three focus on the same biological target: the KRAS gene mutation.

The "Undruggable" Protein That Just Got Drugged

For decades, oncologists called KRAS G12D "undruggable." The protein's structure made it nearly impossible for drugs to bind to it effectively. That changed with a first-in-human clinical trial published in the New England Journal of Medicine that tested ASP3082, a drug developed to destroy — not just block — the KRAS G12D protein from inside cancer cells.

UCLA Health, which co-led the study, enrolled 203 patients across 28 centers in five countries whose cancers had already progressed past prior treatments. Among the 66 patients who received the optimal 600mg weekly intravenous dose, 36% of non-small-cell lung cancer patients saw tumor shrinkage, with median time before disease progression at 8.3 months. In pancreatic ductal adenocarcinoma patients, 24% saw tumor shrinkage and median overall survival hit 10.3 months — in people who had already failed other treatments.

A quarter of late-stage pancreatic cancer patients who had exhausted other options saw their tumors shrink. KRAS G12D drives roughly 40% of all pancreatic cancers and about 5% of non-small-cell lung cancers, according to UCLA Health. No approved treatment for this mutation currently exists. ASP3082 is still investigational, but it has become the most credible candidate in that space.

The Vaccine That Doesn't Need a Factory Line for Each Patient

Memorial Sloan Kettering Cancer Center published Phase 1 results in Nature Medicine for a vaccine called ELI-002 2P, co-led by MSK's Dr. Eileen O'Reilly, MD Anderson's Dr. Shubham Pant, and Elicio Therapeutics' Dr. Christopher M. Haqq.

This vaccine also targets KRAS mutations — relevant in 90-95% of pancreatic cancers and about 50% of colon cancers, according to MSK. The trial enrolled 25 patients at high risk of recurrence after surgery. Approximately two-thirds of patients mounted the desired immune response, meaning their T cells — both CD4 helper cells and CD8 killer cells — multiplied and began targeting KRAS-mutated cancer cells.

What distinguishes this vaccine from the personalized mRNA approach is scalability. Dr. O'Reilly noted: "Having a vaccine that's 'off-the-shelf' would make it easier, faster, and less expensive to treat a larger number of patients."

A custom mRNA vaccine is extraordinary technology. It is also expensive and slow to manufacture per patient. An off-the-shelf version that works could reach vastly more people — a production advantage that receives little attention in mainstream coverage.

A Patient Who Refused to Accept the Math

NPR profiled Vicky Stinson, 65, a retired National Park Service landscape architect from Flagstaff, Arizona. Diagnosed with Stage III pancreatic cancer in 2024, she was told she had "months — not years" to live.

Two years later, she's still here. Stinson benefited from daraxonrasib, a drug that targets and kills cancer cells carrying a common mutation. Her story provides empirical evidence that the treatment math for pancreatic cancer is changing in real time. The five-year survival rate sits at 13%, according to the American Cancer Society. Patients like Stinson are early data points of what a higher number will look like in ten years.

What Mainstream Media Is Getting Wrong

Most coverage treats these breakthroughs as isolated stories. The New York Times frames the KRAS drug as an "impossible idea" made possible, but the framing buries the urgency. NPR focuses heavily on Stinson's personal journey — compelling, but underselling the clinical trial data driving her survival.

Detection AI, a scalable off-the-shelf vaccine, a mutation-degrading drug, and personalized mRNA vaccines are all advancing simultaneously. This is a coordinated scientific moment, not a series of separate human interest stories.

Also underreported: 80% of pancreatic cancers are caught at late stage, according to NPR. The Mayo AI tool addresses that. These treatment advances address what happens after diagnosis. Progress is happening on both fronts at the same time — and that combination is what moves the survival needle.

What It Means for Regular People

If you or someone you know gets a pancreatic cancer diagnosis today, the options are materially better than they were five years ago. The clinical trial record bears this out.

None of these treatments are approved yet. ASP3082 is Phase 1. ELI-002 2P is Phase 1. Daraxonrasib is in trials. The pipeline is real but not yet in your oncologist's standard toolkit.

If you're diagnosed, ask specifically about KRAS mutation status. It drives treatment eligibility for multiple promising therapies simultaneously. Your oncologist may not bring it up. You should.

Pancreatic cancer has been a near-certain death sentence for decades. It still carries terrible odds. But researchers are now attacking it from multiple angles at once — and some patients are living to talk about it.